2,976
Views
11
CrossRef citations to date
0
Altmetric
Original Article

Perfluoroalkyl substances are increased in patients with late-onset ulcerative colitis and induce intestinal barrier defects ex vivo in murine intestinal tissue

, , , , , , & show all
Pages 1286-1295 | Received 16 Apr 2021, Accepted 20 Jul 2021, Published online: 12 Aug 2021

References

  • Everhov ÅH, Halfvarson J, Myrelid P, et al. Incidence and treatment of patients diagnosed with inflammatory bowel diseases at 60 years or older in Sweden. Gastroenterology. 2018;154(3):518–528.
  • GBD 2017 Inflammatory Bowel Disease Collaborators The global, regional, and national burden of inflammatory bowel disease in 195 countries and territories, 1990-2017: a systematic analysis for the global burden of disease study 2017. Lancet Gastroenterol Hepatol. 2020;5(1):17–30.
  • Schoultz I, Keita ÅV. The intestinal barrier and current techniques for the assessment of gut permeability. Cells. 2020;9(8):1909.
  • Roberts CL, Keita AV, Duncan SH, et al. Translocation of crohn’s disease Escherichia coli across M-cells: contrasting effects of soluble plant fibres and emulsifiers. Gut. 2010;59(10):1331–1339.
  • Nair N, Austin C, Curtin P, et al. Association between early-life exposures and inflammatory bowel diseases, based on analyses of deciduous teeth. Gastroenterology. 2020;159(1):383–387.
  • Olsen GW, Burris JM, Ehresman DJ, et al. Half-life of serum elimination of perfluorooctanesulfonate,perfluorohexanesulfonate, and perfluorooctanoate in retired fluorochemical production workers. Environ Health Perspect. 2007;115(9):1298–1305.
  • Huang MC, Robinson VG, Waidyanatha S, et al. Toxicokinetics of 8:2 fluorotelomer alcohol (8:2-FTOH) in male and female hsd:Sprague dawley SD rats after intravenous and gavage administration. Toxicol Rep. 2019;6:924–932.
  • Steenland K, Zhao L, Winquist A, et al. Ulcerative colitis and perfluorooctanoic acid (PFOA) in a highly exposed population of community residents and workers in the mid-Ohio valley. Environ. Health Perspect. 2013;121(8):900–905.
  • Rashid F, Ahmad S, Irudayaraj JMK. Effect of perfluorooctanoic acid on the epigenetic and tight junction genes of the mouse intestine. Toxics. 2020;8(3):64.
  • Zhao W, Zitzow JD, Ehresman DJ, et al. Na+/taurocholate cotransporting polypeptide and apical Sodium-Dependent bile acid transporter are involved in the disposition of perfluoroalkyl sulfonates in humans and rats. Toxicol Sci. 2015;146(2):363–373.
  • Chiang JY. Recent advances in understanding bile acid homeostasis. F1000Res. 2017;6:2029–2028.
  • Duboc H, Rajca S, Rainteau D, et al. Connecting dysbiosis, bile-acid dysmetabolism and gut inflammation in inflammatory bowel diseases. Gut. 2013;62(4):531–539.
  • Lavelle A, Sokol H. Gut microbiota-derived metabolites as key actors in inflammatory bowel disease. Nat Rev Gastroenterol Hepatol. 2020;17(4):223–237.
  • Münch A, Ström M, Söderholm JD. Dihydroxy bile acids increase mucosal permeability and bacterial uptake in human colon biopsies. Scand J Gastroenterol. 2007;42(10):1167–1174.
  • Lee D, Albenberg L, Compher C, et al. Diet in the pathogenesis and treatment of inflammatory bowel diseases. Gastroenterology. 2015;148(6):1087–1106.
  • Fransén K, Franzén P, Magnuson A, et al. Polymorphism in the retinoic acid metabolizing enzyme CYP26B1 and the development of crohn’s disease. PLoS One. 2013;8(8):e72739–6.
  • Drobin K, Assadi G, Hong M-G, et al. Targeted analysis of serum proteins encoded at known inflammatory bowel disease risk loci. Inflamm. Bowel Dis. 2019;25(2):306–316.
  • Lennard-Jones JE. Classification of inflammatory bowel disease. Scand J Gastroenterol Suppl. 1989;170:2–6.
  • Silverberg MS, Satsangi J, Ahmad T, et al. Toward an integrated clinical, molecular and serological classification of inflammatory bowel disease: report of a working party of the 2005 montreal world congress of gastroenterology. Can J Gastroenterol. 2005;19(Suppl A):5A–36A.
  • Salihović S, Dickens AM, Schoultz I, et al. Simultaneous determination of perfluoroalkyl substances and bile acids in human serum using ultra-high-performance liquid chromatography-tandem mass spectrometry. Anal Bioanal Chem. 2020;412(10):2251–2259.
  • Pusceddu MM, Barboza M, Keogh CE, et al. Nod-like receptors are critical for gut-brain axis signalling in mice. J Physiol. 2019;597(24):5777–5797.
  • Chong J, Wishart DS, Xia J. Using MetaboAnalyst 4.0 for comprehensive and integrative metabolomics data analysis. Curr Protoc Bioinformatics. 2019;68(1):1–128.
  • Basu S, Duren W, Evans CR, et al. Sparse network modeling and metscape-based visualization methods for the analysis of large-scale metabolomics data. Bioinformatics. 2017;33(10):1545–1553.
  • Sunderland EM, Hu XC, Dassuncao C, et al. A review of the pathways of human exposure to poly- and perfluoroalkyl substances (PFASs) and present understanding of health effects. J Expo Sci Environ Epidemiol. 2019;29(2):131–147.
  • Steenland K, Kugathasan S, Barr DB. PFOA and ulcerative colitis. Environ Res. 2018;165:317–321.
  • Hammer T, Lophaven SN, Nielsen KR, et al. Dietary risk factors for inflammatory bowel diseases in a high-risk population: results from the faroese IBD study. United European Gastroenterol J. 2019;7(7):924–932.
  • Salim SY, Söderholm JD. Importance of disrupted intestinal barrier in inflammatory bowel diseases. Inflamm Bowel Dis. 2011;17(1):362–381.
  • Schoultz I, Keita ÅV. Cellular and molecular therapeutic targets in inflammatory bowel disease-focusing on intestinal barrier function. Cells. 2019;8(2):193.
  • Eriksen KT, Raaschou-Nielsen O, McLaughlin JK, et al. Association between plasma PFOA and PFOS levels and total cholesterol in a middle-aged Danish population. PLoS One. 2013;8(2):e56969.
  • Steenland K, Tinker S, Frisbee S, et al. Association of perfluorooctanoic acid and perfluorooctane sulfonate with serum lipids among adults living near a chemical plant. Am J Epidemiol. 2009;170(10):1268–1278.
  • Da Violante G, Zerrouk N, Richard I, et al. Evaluation of the cytotoxicity effect of dimethyl sulfoxide (DMSO) on Caco2/TC7 colon tumor cell cultures. Biol Pharm Bullet. 2002;25(12):1600–1603.
  • Hollebeeck S, Raas T, Piront N, et al. Dimethyl sulfoxide (DMSO) attenuates the inflammatory response in the in vitro intestinal caco-2 cell model. Toxicol Lett. 2011;206(3):268–275.
  • Xu Y, Li Y, Scott K, et al. Inflammatory bowel disease and biomarkers of gut inflammation and permeability in a community with high exposure to perfluoroalkyl substances through drinking water. Environ. Res. 2020;181:108923–108928.
  • Ajamian M, Steer D, Rosella G, et al. Serum zonulin as a marker of intestinal mucosal barrier function: may not be what it seems. PLOS One. 2019;14(1):e0210728–10.
  • Meira de-Faria F, Bednarska O, Ström M, et al. Colonic paracellular permeability and circulating zonulin-related proteins. Scand J Gastroenterol. 2021;56(4):424–431.
  • Scharmach E, Buhrke T, Lichtenstein D, et al. Perfluorooctanoic acid affects the activity of the hepatocyte nuclear factor 4 alpha (HNF4α). Toxicol Lett. 2012;212(2):106–112.
  • Ahn S-H, Shah YM, Inoue J, et al. Hepatocyte nuclear factor 4alpha in the intestinal epithelial cells protects against inflammatory bowel disease. Inflamm Bowel Dis. 2008;14(7):908–920.
  • Chiang JYL. Hepatocyte nuclear factor 4alpha regulation of bile acid and drug metabolism. Expert Opin Drug Metab Toxicol. 2009;5(2):137–147.
  • Bijland S, Rensen PCN, Pieterman EJ, et al. Perfluoroalkyl sulfonates cause alkyl chain length-dependent hepatic steatosis and hypolipidemia mainly by impairing lipoprotein production in APOE*3-Leiden CETP mice. Toxicol Sci. 2011;123(1):290–303.
  • Behr A-C, Kwiatkowski A, Ståhlman M, et al. Impairment of bile acid metabolism by perfluorooctanoic acid (PFOA) and perfluorooctanesulfonic acid (PFOS) in human HepaRG hepatoma cells. Arch Toxicol. 2020;94(5):1673–1686.
  • Ejderhamn J, Strandvik B. Serum bile acids in relation to disease activity and intake of dietary fibers in juvenile ulcerative colitis. Digestion. 1991;50(3-4):162–169.
  • Gnewuch C, Liebisch G, Langmann T, et al. Serum bile acid profiling reflects enterohepatic detoxification state and intestinal barrier function in inflammatory bowel disease. World J Gastroenterol. 2009;15(25):3134–3141.
  • Münch A, Söderholm JD, Ost A, et al. Low levels of bile acids increase bacterial uptake in colonic biopsies from patients with collagenous colitis in remission. Aliment Pharmacol Ther. 2011;33(8):954–960.
  • Meihoff WE, Kern F. Bile salt malabsorption in regional ileitis, ileal resection and mannitol-induced diarrhea. J Clin Invest. 1968;47(2):261–267.
  • Halfvarson J, Brislawn CJ, Lamendella R, et al. Dynamics of the human gut microbiome in inflammatory bowel disease. Nat Microbiol. 2017;2(5):1–9.
  • Lenicek M, Duricova D, Komarek V, et al. Bile acid malabsorption in inflammatory bowel disease: assessment by serum markers. Inflamm. Bowel Dis. 2011;17(6):1322–1327.